{"id":"NCT00150813","sponsor":"UCB Pharma SA","briefTitle":"Monotherapy With Levetiracetam in Patients Suffering From Epilepsy.","officialTitle":"A Multicenter, Open-label, Follow-up Trial Evaluating the Long-term Safety of Levetiracetam Individualized Dose From 1000 to 3000 mg/Day (Oral Tablets of 500 mg b.i.d.), Used as Monotherapy in Subjects (â‰¥ 16 Years) Suffering From Epilepsy and Coming From the N01061 or the N01093 Trials.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-08-10","primaryCompletion":"2007-05-29","completion":"2007-05-29","firstPosted":"2005-09-08","resultsPosted":"2018-10-01","lastUpdate":"2018-11-21"},"enrollment":66,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Epilepsy, Tonic-clonic"],"interventions":[{"type":"DRUG","name":"Levetiracetam","otherNames":["Keppra"]}],"arms":[{"label":"Levetiracetam","type":"EXPERIMENTAL"}],"summary":"An open-label follow-up trial assessing the long term safety of levetiracetam as per adverse events reporting.","primaryOutcome":{"measure":"Percentage Participants With Treatment Emergent Adverse Events","timeFrame":"From the Entry Visit until up to 2 weeks after the last drug intake, up to 93 weeks","effectByArm":[{"arm":"Levetiracetam","deltaMin":27.3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":null},"locations":{"siteCount":21,"countries":["Czechia","Hungary","Poland","Sweden"]},"refs":{"pmids":[],"seeAlso":["http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":66},"commonTop":[]}}